DE60312513D1 - Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100 - Google Patents

Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100

Info

Publication number
DE60312513D1
DE60312513D1 DE60312513T DE60312513T DE60312513D1 DE 60312513 D1 DE60312513 D1 DE 60312513D1 DE 60312513 T DE60312513 T DE 60312513T DE 60312513 T DE60312513 T DE 60312513T DE 60312513 D1 DE60312513 D1 DE 60312513D1
Authority
DE
Germany
Prior art keywords
apo
apolipoprotein
detection
methods
concerns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60312513T
Other languages
English (en)
Other versions
DE60312513T2 (de
Inventor
Jamila Najib
Zouher Majd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of DE60312513D1 publication Critical patent/DE60312513D1/de
Application granted granted Critical
Publication of DE60312513T2 publication Critical patent/DE60312513T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Steroid Compounds (AREA)
  • Light Receiving Elements (AREA)
DE60312513T 2002-06-19 2003-06-19 Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100 Expired - Fee Related DE60312513T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207542A FR2841249A1 (fr) 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
FR0207542 2002-06-19
PCT/FR2003/001888 WO2004000884A2 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100

Publications (2)

Publication Number Publication Date
DE60312513D1 true DE60312513D1 (de) 2007-04-26
DE60312513T2 DE60312513T2 (de) 2007-12-06

Family

ID=29719858

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60312513T Expired - Fee Related DE60312513T2 (de) 2002-06-19 2003-06-19 Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100

Country Status (11)

Country Link
US (1) US20050152900A1 (de)
EP (1) EP1513878B1 (de)
JP (1) JP2006515561A (de)
AT (1) ATE356832T1 (de)
AU (1) AU2003267493A1 (de)
CA (1) CA2489057A1 (de)
DE (1) DE60312513T2 (de)
DK (1) DK1513878T3 (de)
ES (1) ES2283803T3 (de)
FR (1) FR2841249A1 (de)
WO (1) WO2004000884A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207505A1 (en) * 2004-03-29 2007-09-06 Shibayagi Co., Ltd. Method for Mesurement of Apoliporotein B-48 and its Use
WO2007058588A1 (en) * 2005-11-18 2007-05-24 T.A.C Thrombosis And Coagulation Aktiebolag Monoclonal antibodies against apolipoprotein m
AU2007230967A1 (en) * 2006-03-23 2007-10-04 Breyer, Emelita De Guzman Apolipoprotein fingerprinting technique
JP5511669B2 (ja) 2007-10-02 2014-06-04 セラノス， インコーポレイテッド モジュール式ポイントオブケアデバイスおよびその使用
JP5832723B2 (ja) * 2009-03-06 2015-12-16 協和メデックス株式会社 可溶性インターロイキン−２受容体定量用標準品
EP2408812B1 (de) * 2009-03-17 2015-12-16 CardioVax, LLC Immunmodulatorische Verfahren und Systeme zur Behandlung und/oder Prävention von Atherosklerose sowie zugehörige Proteine, Peptide und Zusammensetzungen
AU2010319323B2 (en) 2009-11-14 2015-01-15 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) * 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
JP2013544243A (ja) 2010-11-12 2013-12-12 シーダース シナイ メディカル センター 動脈瘤の治療及び／又は予防のための免疫調節方法及びシステム
JP2014516913A (ja) 2010-11-12 2014-07-17 シーダース シナイ メディカル センター 高血圧の治療及び／又は予防のための免疫調節方法及びシステム
CN106290159A (zh) 2011-01-21 2017-01-04 提拉诺斯公司 样品使用最大化的系统和方法
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US11008628B1 (en) * 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
CN106053793A (zh) * 2016-06-20 2016-10-26 诺莱生物医学研究院（北京）有限公司 一种快速检测乳糜血的免疫层析试纸卡及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193926A (ja) * 1984-03-15 1985-10-02 Tokyo Daigaku 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
JPS617299A (ja) * 1984-06-20 1986-01-13 Dai Ichi Pure Chem Co Ltd ヒトアポリポ蛋白ｂ４８に高い特異性を有する単クローン性抗体
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors

Also Published As

Publication number Publication date
DK1513878T3 (da) 2007-07-16
AU2003267493A1 (en) 2004-01-06
US20050152900A1 (en) 2005-07-14
CA2489057A1 (fr) 2003-12-31
WO2004000884A2 (fr) 2003-12-31
ES2283803T3 (es) 2007-11-01
JP2006515561A (ja) 2006-06-01
FR2841249A1 (fr) 2003-12-26
EP1513878B1 (de) 2007-03-14
WO2004000884A3 (fr) 2004-04-08
EP1513878A2 (de) 2005-03-16
DE60312513T2 (de) 2007-12-06
ATE356832T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
ATE356832T1 (de) Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100
ES2054617T3 (es) Nuevo metodo para la deteccion y/o determinacion cuantitativa de agentes ligantes especificos y sus correspondientes sustancias ligables.
BR9710836A (pt) Ensaio de analitos usando marcas em partìculas
DE60204418D1 (de) "High-Density-Lipoprotein"-Testvorrichtung und Verfahren
WO2003057851A3 (en) Binding proteins as biosensors
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
DE502004008216D1 (de) Vorrichtung und verfahren zur simultanen durchführung von blutgruppenbestimmung, serumgegenprobe und antikörpersuch-test
ATE408829T1 (de) Verfahren und assaykits zum nachweis mononuklearer zellphänotypen
CA2519504A1 (en) Combination assay for alcohol and drugs of abuse
ATE449963T1 (de) Immunoassays unter verwendung von sers (surface enhanced raman scattering)
ATE151883T1 (de) Verfahren zum nachweis freier igf-i, igf-ii, und gh spiegel in körperflüssigkeiten
ATE384952T1 (de) Enzymhemmungsimmunverfahren
DE60029413D1 (de) Enzymatische messung von mycophenolsäure
DE60318435D1 (de) Universeller biosensor und verfahren zur verwendung
ATE347105T1 (de) Verfahren, assay und kit zur quantifizierung von hiv-proteasehemmer
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
DE60131281D1 (de) Verfahren zum messen von gesamt-homocystein
ATE500505T1 (de) Enzymhemmungsimmunverfahren
WO2002098919A3 (en) Method for apo ciii measurement in apob and non apob containing particles
DE60216482D1 (de) Zusammensetzungen und verfahren zum bestimmen von aa4rp
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
Da Vela et al. Evaluation of an automated system for amylase detection in forensic samples
KR890016376A (ko) 혈액중의 특이한 결합물질 검출방법 및 상기 방법을 수행하기 위한 시험키트
WO2001044779A3 (en) Method of processing and testing powdered samples using immunochromatographic strip tests
WO2000034777A3 (de) Verfahren zur bestimmung von biologischen langzeitwirkungen von stoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee